Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.56 |
| ▸ | PPARD | Q03181 | 7/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | PDE2A | O00408 | 3/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529966 | 1.00 | PPARA (0.56) | PPARAPPARDPPARGFFAR1PDE2A | |
| SCHEMBL4921482 | 0.86 | CYP11B1 (0.53) | PPARAPPARDPPARG | |
| SCHEMBL4921476 | 0.86 | CYP11B1 (0.53) | PPARAPPARDPPARG | |
| SCHEMBL14413276 | 0.86 | CYP11B1 (0.53) | PPARAPPARDPPARG | |
| SCHEMBL14378523 | 0.84 | PPARD (0.55) | PPARAPPARDPPARGFFAR1 | |
| SCHEMBL14378629 | 0.83 | PPARA (0.57) | PPARAPPARDPPARGFFAR1PDE2A | |
| SCHEMBL4819560 | 0.83 | PPARA (0.57) | PPARAPPARDPPARGFFAR1PDE2A | |
| SCHEMBL4758807 | 0.82 | PPARD (0.59) | PPARAPPARDPPARGFFAR1 | |
| SCHEMBL4758808 | 0.82 | PPARD (0.59) | PPARAPPARDPPARGFFAR1 | |
| SCHEMBL14378525 | 0.81 | PPARD (0.55) | PPARAPPARDPPARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007106469-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | GOT2, PC, GOT1 | PPARA 213/4885PPARD 243/4885PPARG 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.